Drug-induced alopecia after dupilumab therapy

Abstract

Dupilumab is a selectively immunosuppressive biologic therapy that treats chronic moderate-to-severe atopic dermatitis through inhibiting signaling transmission of interleukins (IL) 4 and 13. It is often prescribed when patients do not respond to or cannot tolerate conventional topical or systemic therapies. Most commonly reported side effects include injection site reactions, eye and eyelid inflammation, and nasopharyngitis.1,2 This case report highlights a patient who experienced drug-induced alopecia at 18 weeks on dupilumab.